JointHealth™ express   December 11, 2012

Reminder: Do you have rheumatoid arthritis? We want your valuable input

Two weeks ago today, Arthritis Consumer Experts (ACE) sent out a JointHealth™ express announcing that we are gathering patient input to submit to the Common Drug Review (CDR). We are very pleased to report that many of you were keen to participate.

If you have not yet had a chance to get involved, there is still time. The CDR continues to accept input on the manufacturer’s submission for a new formulation of abatacept (Orencia®) for the treatment of rheumatoid arthritis (RA). Abatacept is currently administered by intravenous infusion, but the medication has been reformulated to be injectable.

So, if you live with RA, or care for someone with the disease, and you would like to provide your input, please contact us by Monday, December 17. This will allow us enough time to include your submission and meet the deadline, which is December 21, 2012.

Email us at to provide your input or arrange for a phone interview.

For more information about the CDR, the process for submitting input, and for a list of the questions, please click here.

To all those who already responded, thank you!